Literature DB >> 25864647

Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway.

Han Li1, Guo-feng Pan2, Zhen-zhou Jiang1, Jing Yang1, Li-xin Sun1, Lu-yong Zhang1.   

Abstract

AIM: To investigate the anticancer mechanisms of triptolide, a diterpenoid isolated from the plant Tripterygium wilfordii Hook F, against human breast cancer cells and the involvement of the estrogen receptor-α (ERα)-mediated signaling pathway in particular.
METHODS: Human breast cancer ERα-positive MCF-7 cells and ERα-negative MDA-MB-231 cells were tested. PrestoBlue assay was used to evaluate the cell viability. The levels of ERα mRNA and protein were detected with real-time PCR and immunoblotting, respectively. Mouse models of MCF-7 or MDA-MB-231 xenograft tumors were treated with triptolide (0.4 mg·kg(-1)·d(-1), po) or a selective estrogen receptor modulator tamoxifen (mg·kg(-1)·d(-1), po) for 3 weeks, and the tumor weight and volume were measured.
RESULTS: Triptolide (5-200 nmol/L) dose-dependently inhibited the viability of both MCF-7 and MDA-MB-231 cells, with a more potent inhibition on MCF-7 cells. Knockdown of ERα in MCF-7 cells by siRNA significantly attenuated the cytotoxicity of triptolide, whereas overexpression of ERα in MDA-MB-231 cells markedly enhanced the cytotoxicity. Triptolide dose-dependently decreased the expression of ERα in MCF-7 cells and MCF-7 xenograft tumors. Furthermore, treatment of MCF-7 cells with triptolide inhibited the phosphorylation of ERK1/2 in dose- and time-dependent manners. In the mice xenografted with MCF-7 cells, treatment with triptolide or tamoxifen resulted in significant reduction in the tumor weight and volume. Similar effects were not obtained in the mice xenografted with MDA-MB-231 cells.
CONCLUSION: The anticancer activity of triptolide against ERα-positive human breast cancer is partially mediated by downregulation of the ERα-mediated signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25864647      PMCID: PMC4422943          DOI: 10.1038/aps.2014.162

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  26 in total

Review 1.  Estrogen-receptor biology: continuing progress and therapeutic implications.

Authors:  C Kent Osborne; Rachel Schiff
Journal:  J Clin Oncol       Date:  2005-03-10       Impact factor: 44.544

Review 2.  Biological determinants of endocrine resistance in breast cancer.

Authors:  Elizabeth A Musgrove; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

3.  Oligonucleosome DNA fragmentation of caspase 3 deficient MCF-7 cells in palmitate-induced apoptosis.

Authors:  D V Semenov; P A Aronov; E V Kuligina; M O Potapenko; V A Richter
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2004-10       Impact factor: 1.381

4.  Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells.

Authors:  M H Jeng; W Yue; A Eischeid; J P Wang; R J Santen
Journal:  Breast Cancer Res Treat       Date:  2000-08       Impact factor: 4.872

Review 5.  Mechanisms of estrogen action.

Authors:  S Nilsson; S Mäkelä; E Treuter; M Tujague; J Thomsen; G Andersson; E Enmark; K Pettersson; M Warner; J A Gustafsson
Journal:  Physiol Rev       Date:  2001-10       Impact factor: 37.312

6.  Triptolide inhibits COX-2 expression by regulating mRNA stability in TNF-α-treated A549 cells.

Authors:  Lixin Sun; Shuang Zhang; Zhenzhou Jiang; Xin Huang; Tao Wang; Xiao Huang; Han Li; Luyong Zhang
Journal:  Biochem Biophys Res Commun       Date:  2011-11-10       Impact factor: 3.575

7.  Hyperexpression of mitogen-activated protein kinase in human breast cancer.

Authors:  V S Sivaraman; H Wang; G J Nuovo; C C Malbon
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

8.  Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation.

Authors:  Lesley-Ann Martin; Ian Farmer; Stephen R D Johnston; Simak Ali; Chris Marshall; Mitch Dowsett
Journal:  J Biol Chem       Date:  2003-05-29       Impact factor: 5.157

9.  Effects of triptolide from Tripterygium wilfordii on ERalpha and p53 expression in two human breast cancer cell lines.

Authors:  Jing Liu; Zhenzhou Jiang; Jingwei Xiao; Yun Zhang; Sensen Lin; Weigang Duan; Jincheng Yao; Chunhui Liu; Xin Huang; Tao Wang; Zhongliang Liang; Rongrong Wang; Shuang Zhang; Luyong Zhang
Journal:  Phytomedicine       Date:  2009-06-12       Impact factor: 5.340

10.  Triptolide induces apoptosis of breast cancer cells via a mechanism associated with the Wnt/β-catenin signaling pathway.

Authors:  Hongmin Shao; Jinghua Ma; Tianhua Guo; Rongrong Hu
Journal:  Exp Ther Med       Date:  2014-05-26       Impact factor: 2.447

View more
  10 in total

1.  Triptolide induces autophagy and apoptosis through ERK activation in human breast cancer MCF-7 cells.

Authors:  Huan Gao; Yue Zhang; Lei Dong; Xiao-Yu Qu; Li-Na Tao; Yue-Ming Zhang; Jing-Hui Zhai; Yan-Qing Song
Journal:  Exp Ther Med       Date:  2018-02-01       Impact factor: 2.447

Review 2.  Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine.

Authors:  Hua Luo; Chi Teng Vong; Hanbin Chen; Yan Gao; Peng Lyu; Ling Qiu; Mingming Zhao; Qiao Liu; Zehua Cheng; Jian Zou; Peifen Yao; Caifang Gao; Jinchao Wei; Carolina Oi Lam Ung; Shengpeng Wang; Zhangfeng Zhong; Yitao Wang
Journal:  Chin Med       Date:  2019-11-06       Impact factor: 5.455

3.  A Novel Immunocompetent Mouse Model of Pancreatic Cancer with Robust Stroma: a Valuable Tool for Preclinical Evaluation of New Therapies.

Authors:  Kaustav Majumder; Nivedita Arora; Shrey Modi; Rohit Chugh; Alice Nomura; Bhuwan Giri; Rajinder Dawra; Sundaram Ramakrishnan; Sulagna Banerjee; Ashok Saluja; Vikas Dudeja
Journal:  J Gastrointest Surg       Date:  2015-11-18       Impact factor: 3.452

4.  Anti-cancer and Sensibilisation Effect of Triptolide on Human Epithelial Ovarian Cancer.

Authors:  Hui Hu; Liping Luo; Fei Liu; Danghua Zou; Sihong Zhu; Buzhen Tan; Tingtao Chen
Journal:  J Cancer       Date:  2016-10-23       Impact factor: 4.207

Review 5.  Phytochemicals and PI3K Inhibitors in Cancer-An Insight.

Authors:  Vasanti Suvarna; Manikanta Murahari; Tabassum Khan; Pramila Chaubey; Preeti Sangave
Journal:  Front Pharmacol       Date:  2017-12-14       Impact factor: 5.810

6.  L-Carnitine reduces reactive oxygen species/endoplasmic reticulum stress and maintains mitochondrial function during autophagy-mediated cell apoptosis in perfluorooctanesulfonate-treated renal tubular cells.

Authors:  Yuan-Chii Gladys Lee; Hsiu-Chu Chou; Yen-Ting Chen; Szu-Yu Tung; Tsui-Ling Ko; Batsaikhan Buyandelger; Li-Li Wen; Shu-Hui Juan
Journal:  Sci Rep       Date:  2022-03-18       Impact factor: 4.379

7.  Triptolide inhibits matrix metalloproteinase-9 expression and invasion of breast cancer cells through the inhibition of NF-κB and AP-1 signaling pathways.

Authors:  On-Yu Hong; Hye-Yeon Jang; Kwang-Hyun Park; Young-Ju Jeong; Jong-Suk Kim; Hee Suk Chae
Journal:  Oncol Lett       Date:  2021-05-27       Impact factor: 2.967

8.  Sex-Related Differences of Lipid Metabolism Induced by Triptolide: The Possible Role of the LXRα/SREBP-1 Signaling Pathway.

Authors:  Zhenzhou Jiang; Xiao Huang; Shan Huang; Hongli Guo; Lu Wang; Xiaojiaoyang Li; Xin Huang; Tao Wang; Luyong Zhang; Lixin Sun
Journal:  Front Pharmacol       Date:  2016-03-31       Impact factor: 5.810

9.  Establishment of a murine breast tumor model by subcutaneous or orthotopic implantation.

Authors:  Yi Zhang; Gan-Lin Zhang; Xu Sun; Ke-Xin Cao; Cong Ma; Nan Nan; Guo-Wang Yang; Ming-Wei Yu; Xiao-Min Wang
Journal:  Oncol Lett       Date:  2018-02-23       Impact factor: 2.967

10.  Membrane protein-chimeric liposome-mediated delivery of triptolide for targeted hepatocellular carcinoma therapy.

Authors:  Yanwen Zheng; Fanhua Kong; Songyang Liu; Xi Liu; Dongni Pei; Xiongying Miao
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.